Heol-L Tablet SR is a combination pharmaceutical formulation containing Levosulpiride 75mg and Rabeprazole 20mg, designed for the management of gastrointestinal disorders characterized by dyspepsia, gastroesophageal reflux disease (GERD), and functional dysmotility. Levosulpiride, a selective dopamine D2 receptor antagonist, facilitates gastrointestinal motility by enhancing gastric emptying and alleviating symptoms such as nausea, bloating, and abdominal discomfort. Rabeprazole, a proton pump inhibitor, effectively suppresses gastric acid secretion by inhibiting the H+/K+ ATPase enzyme system in gastric parietal cells, thereby promoting mucosal healing and reducing acid-related irritation. The sustained-release (SR) formulation ensures prolonged therapeutic plasma concentrations, optimizing symptom control and improving patient compliance through once-daily dosing. Heol-L Tablet SR is indicated for patients with acid peptic disorders accompanied by impaired gastric motility, providing symptomatic relief and promoting mucosal recovery. It should be used under medical supervision, with caution in patients with a history of hypersensitivity to sulpiride, proton pump inhibitors, or related compounds. Common adverse effects may include headache, dizziness, and mild gastrointestinal disturbances. Regular monitoring is advised to assess therapeutic response and detect any potential adverse reactions. This combination therapy offers an effective approach to managing complex upper gastrointestinal conditions by addressing both acid suppression and motility enhancement.